Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412909 | 0.76 | — | — | |
| 2,6-Diaminopurine SCHEMBL29444619 | 0.75 | GDA (0.48) | PDPK1GDA | |
| 2,6-Diaminopurine SCHEMBL24052 | 0.75 | GDA (0.48) | PDPK1GDA | |
| SCHEMBL325148 | 0.75 | CDK1 (0.33) | — | |
| SCHEMBL669639 | 0.73 | — | — | |
| 2,6-Diaminopurine SCHEMBL6423146 | 0.73 | GDA (0.47) | PDPK1GDA | |
| 2,6-Diaminopurine SCHEMBL8757968 | 0.73 | GDA (0.47) | PDPK1GDA | |
| SCHEMBL8506347 | 0.72 | GDA (0.34) | GDA | |
| SCHEMBL8523000 | 0.72 | INSR (0.39) | — | |
| SCHEMBL490902 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3394118-A1 | DETERGENT ADDITIVE FOR FUEL, AND COPOLYMERS USABLE IN SAID APPLICATION | Total Marketing Services (FR) | 2018-10-31 | — | — | EP | claimed |
| WO-2017109369-A1 | DETERGENT ADDITIVE FOR FUEL, AND COPOLYMERS USABLE IN SAID APPLICATION | TOTAL MARKETING SERVICES (FR) | 2017-06-29 | — | — | WO | claimed |
| EP-3512860-B1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB PHARMA INC (CA) | 2020-11-25 | — | — | EP | disclosed |
| EP-3394118-A1 | DETERGENT ADDITIVE FOR FUEL, AND COPOLYMERS USABLE IN SAID APPLICATION | Total Marketing Services (FR) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017109369-A1 | DETERGENT ADDITIVE FOR FUEL, AND COPOLYMERS USABLE IN SAID APPLICATION | TOTAL MARKETING SERVICES (FR) | 2017-06-29 | — | — | WO | disclosed |
| US-9156874-B2 | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs | NANJING MOLECULAR RESEARCH, INC. (CN) | 2015-10-13 | — | — | US | disclosed |
| US-9095599-B2 | O-(substituted benzyl) phosphoramidate compounds and therapeutic use | NANJING MOLECULAR RESEARCH, INC. (CN) | 2015-08-04 | — | — | US | disclosed |
| US-20140038916-A1 | O-(SUBSTITUTED BENZYL) PHOSPHORAMIDATE COMPOUNDS AND THERAPEUTIC USE | NANJING MOLECULAR RESEARCH, INC. (CN) | 2014-02-06 | — | — | US | disclosed |
| WO-2013187978-A1 | DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS | NANJING MOLECULAR RESEARCH, INC. (CN) | 2013-12-19 | — | — | WO | disclosed |
| US-20130210757-A1 | DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS | NANJING MOLECULAR RESEARCH, INC. (CN) | 2013-08-15 | — | — | US | disclosed |
| WO-2012094248-A1 | O-(SUBSTITUTED BENZYL) PHOSPHORAMIDATE COMPOUNDS AND THERAPEUTIC USE | NANJING MOLECULAR RESEARCH, INC. (CN) | 2012-07-12 | — | — | WO | disclosed |
| US-7585851-B2 | 3′-prodrugs of 2′-deoxy-β-L-nucleosides | IDENIX PHARMACEUTICALS, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-6214187-B1 | ANALYZING NUCLEIC ACID SEQUENCES | MOSAIC TECHNOLOGIES | 2001-04-10 | — | — | US | disclosed |
| EP-1086248-A1 | DENATURING GRADIENT AFFINITY ELECTROPHORESIS AND METHODS OF USE THEREOF | MOSAIC TECHNOLOGIES, INC. (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1068518-A2 | PURIFICATION AND DETECTION PROCESSES USING REVERSIBLE AFFINITY ELECTROPHORESIS | Exact Sciences Corporation (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999066078-A1 | DENATURING GRADIENT AFFINITY ELECTROPHORESIS AND METHODS OF USE THEREOF | MOSAIC TECHNOLOGIES (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999045374-A2 | PURIFICATION AND DETECTION PROCESSES USING REVERSIBLE AFFINITY ELECTROPHORESIS | MOSAIC TECHNOLOGIES (US) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038916-A1 | O-(SUBSTITUTED BENZYL) PHOSPHORAMIDATE COMPOUNDS AND THERAPEUTIC USE | PNP, PAICS, TYMP | PDPK1 880/4885GDA 92/4885 |
| US-20130210757-A1 | DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS | PNP, PAICS, NTPCR | PDPK1 780/4885GDA 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.